Literature DB >> 20111873

Polymorphous lymphoproliferative disorder: a clinicopathological analysis.

Naoto Nakamichi1, Naoki Wada, Masaharu Kohara, Shirou Fukuhara, Haruo Sugiyama, Hiroyasu Ogawa, Masayuki Hino, Akihisa Kanamaru, Yuzuru Kanakura, Eiichi Morii, Katsuyuki Aozasa.   

Abstract

Lymphoproliferative disorder (LPD) with polymorphous composition of proliferation (polymorphous LPD), containing large lymphoid cells together with small lymphocytes, plasma cells, macrophages, and/or eosinophils, is found in individuals with immunodeficiency conditions. Clinicopathological findings in 19 cases of polymorphous LPD registered with the Osaka Lymphoma Study Group, Osaka, Japan, were analyzed; they represented 0.4% of the registered cases. In six cases, there was a history of rheumatoid arthritis; five of them had received immunosuppressive agents. There were no acquired immunodeficiency syndrome cases or organ transplant recipients. Southern blotting and/or polymerase chain reaction (PCR)-based clonality analysis revealed monoclonal B cell and T cell proliferation in eight and six cases (B- and T-LPD), respectively, and polyclonality in one. In B-LPD, there was polymorphous proliferation, containing large B-lymphoid cells, while medium-to-large T lymphoid cells with occasional eosinophilic infiltration were seen in T-LPD. Epstein-Barr virus (EBV) was detected in three of eight B-LPD, four of six T-LPD, and one of one polyclonal LPD. The prognosis was not favorable; the 3-year overall survival rate was 49.7 +/- 17.3%. Thus, polymorphous LPD is relatively rare in Japan and is a heterogeneous disease with monoclonal proliferation of B or T cells; additionally, it is occasionally EBV-associated, and behaves as an aggressive lymphoma.

Entities:  

Mesh:

Year:  2010        PMID: 20111873     DOI: 10.1007/s00428-010-0880-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  15 in total

1.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

Review 2.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.

Authors:  M H Ellman; H Hurwitz; C Thomas; M Kozloff
Journal:  J Rheumatol       Date:  1991-11       Impact factor: 4.666

4.  Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy.

Authors:  O W Kamel; L M Weiss; M van de Rijn; T V Colby; D W Kingma; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

Review 5.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Post-transplant lymphoproliferative disorders.

Authors:  K J Lewin
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

Review 8.  Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update.

Authors:  Eric Toussirot; Jean Roudier
Journal:  Joint Bone Spine       Date:  2007-06-08       Impact factor: 4.929

9.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

Authors:  Wen-hai Feng; Jeffrey I Cohen; Steven Fischer; Li Li; Michael Sneller; Raphael Goldbach-Mansky; Nancy Raab-Traub; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

Review 10.  Culture, brain death, and transplantation.

Authors:  Kerry W Bowman; Shawn A Richard
Journal:  Prog Transplant       Date:  2003-09       Impact factor: 1.065

View more
  3 in total

1.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

2.  Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases.

Authors:  Wen Xue; Yan Sheng; Xiangqin Weng; Yongmei Zhu; Yan Zhao; Pengpeng Xu; Xiaochun Fei; Xiaoyan Chen; Li Wang; Weili Zhao
Journal:  Front Med       Date:  2015-11-11       Impact factor: 4.592

3.  Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience.

Authors:  Ira Kokovic; Barbara Jezersek Novakovic; Petra Cerkovnik; Srdjan Novakovic
Journal:  Radiol Oncol       Date:  2014-04-25       Impact factor: 2.991

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.